Drug makers have tripled the prices of top Medicare drugs
In 2021, Medicare spent nearly $81 billion on these 25 drugs.
arstechnica.com
For nearly all the drugs, the price hikes far outstripped the rate of inflation, with increases ranging from 20 percent to 739 percent during the drugs' lifetimes on the market. Only one of the top 25 drugs—Trelegy Ellipta, an inhaler for asthma and chronic lung conditions—had price increases that were below the rate of inflation during its time on the market. Since its initial release in 2017, Trelegy Ellipta's price increased only 20 percent, compared with a general inflation rate of 23 percent.